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Traditionally, three models of programmed cell death (PCD) have been proposed, according to the observations made during the second part of century XX: type I cell death associated with
heterophagy (apoptosis), type II cell death associated with autophagy (autophagic death) and type III without digestion implicated (necrosis). However, different types of necrosis as a regulated
process have been recently described, such as necroptosis, parthanatos, oxytosis/ferroptosis, (N)ETosis and pyroptosis. In general, regulated necrosis is described as a dysregulation of redox
metabolome, which curses in an energetic depletion or a high level of redox species.
PARP1 (Poly-ADP-Ribose Polymerase 1) is a nuclear protein which catalyze formation of ADP-ribose from NAD+. Under single or double strand breaks (SSB, DSB), PARP1 becomes active and recruits
protein for DNA repairing by PAR adding (PARylation). Despiste this protective role, PARP1 has been related to several models of cell death, as well as some human diseases, such as
neurodegeneration.
Role of PARP in cell death
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In the last two decades, paradigm about cell death has changed from three well-differentiated models (apoptosis, autophagic death, necrosis) and added several subtypes of necrosis as a regulated
process. The limits among them are diffused, due to sharing some features and interplay. PARP plays an important role by modulating several types of death and has been related to common
human pathologies, as cancer or Parkinson. Therefore, understanding completely the role of PARP and parthanatos in human biology is needed to achieve a successful therapy.
Parkinson
PARP is overexpressed in dopaminergic neurons, increasing susceptibility for parthanatos.
Several hypothesis has been suggested to explain dopaminergic death in Parkinson involving
PARP, such as (i) Glu-induced excitotoxicity leading to ROS formation, (ii) AIMP2 accumulation
by Parkin inactivation promotes PARP activation and (iii) mitochondrial dysfuction leading to cell
death by Parkin inactivation (damaged mitochondria can not be eliminated) and PARP
activation (impaired genesis of new mitochondria).
Cancer
Currently, there are several PARP inhibitors in development as treatment against solid tumors,
such as breast. BRCA and PARP allow repairing of DSB by homologous repair and SSB by base
excision repair, respectively. If BRCA is mutated, PARP inactivation causes genomic instability,
which leads to non-viable genetic errors and, finally, cell death. Furthermore, PARP inhibitors
can be used as a complement or alternative to hormone-depending cancer treatments, since
PARP interacts with Estrogen, Prostagen and Androgen receptors and promotes their function
PARP in human disease
Apoptosis
In spite of PAR formation can be occur prior to apoptosis to detecting DNA breaks, an excess of
PARP1 activity and PAR prevents apoptosis, which is a highly expending process in terms of ATP
Thus, inactivation of PARP1 by cleavage is necessary in order to activate and realize apoptosis,
both intrinsic (not shown) and extrinsic pathway.
Autophagy
The expenditure of ATP during parthanatos leads to a higher AMP/ATP ratio and, thus, an
increased AMPK activity. Completing a feedforward loop, AMPK can phosphorylate PARP1 and
enhance its activity.
Parthanatos
Parthanatos is a new model of regulated necrosis characterized by the overactivation of PARP1.
When DNA damage is profound, PARP-1 activated and produces long-chained, branched
polymers of PAR, through the expenditure of ATP to regenerate NAD+. This energy depletion
leads to externalization of phosphatidylserine, dissipation of the mitochondrial membrane
potential, translocation of AIF from the mitochondria to the nucleus, large-scale DNA
fragmentation (~50 kb) and chromatin condensation, followed by cell death.
Necroptosis
The interplay between PAR and necroptosis is not fully understood, in spite of PAR enhances
necroptotic death. Both necroptosis and parthanatos are inflammatory process, due to NF-κB
activation (not shown) and release of Danger-associated molecular patterns (DAMPs), such as
HMGB-1.
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